σ-1 receptors in major depression and anxiety

Expert Review of Neurotherapeutics

Volumn 9, Issue 7, 2009, Pages 1021-1034

  Kulkarni, Shrinivas K ^a   Dhir, Ashish ^b  

^a PANJAB UNIVERSITY   (India)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

1 receptor; Anxiety; Major depression; Monoamine; Neuritogenesis

Indexed keywords

1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE; 1 CYCLOPROPYLMETHYL 4 [2 (4 FLUOROPHENYL) 2 OXOETHYL]PIPERIDINE; 1 PHENYLCYCLOHEXANECARBOXYLIC ACID 2 MORPHOLINOETHYL ESTER; 1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; ALPHA (4 FLUOROPHENYL) 4 (5 FLUORO 2 PYRIMIDINYL) 1 PIPERAZINEBUTANOL; AMFEBUTAMONE; BD 1063; BERBERINE; CRA 0450; DIZOCILPINE; DTG; ELIPRODIL; FLUOXETINE; FLUVOXAMINE; FUZLOCILLIN; HALOPERIDOL; IGMESINE; JO 1748; METHAMPHETAMINE; N [2 (3,4 DICHLOROPHENYL)ETHYL] 2 DIMETHYLAMINO N METHYLETHYLAMINE; N [2 (3,4 DICHLOROPHENYL)ETHYL] N METHYL 2 (1 PYRROLIDINYL)ETHYLAMINE; N ALLYLNORMETAZOCINE; N,N DIMETHYLTRYPTAMINE; NEUROSTEROID; OMEGA CONOTOXIN; OPC 14523; OPIATE AGONIST; OPIATE ANTAGONIST; OPIPRAMOL; PANAMESINE; PAROXETINE; PENTAZOCINE; PRASTERONE; PRASTERONE SULFATE; PREGNENOLONE SULFATE; PROGESTERONE; R 278995; S 21377; S 21378; SIGMA 1 OPIATE RECEPTOR; UMB 23; UMB 82; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ANXIETY DISORDER; BINDING SITE; BRAIN; BRAIN REGION; CLINICAL PRACTICE; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DOPAMINERGIC TRANSMISSION; DORSAL RAPHE NUCLEUS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BINDING; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; HERBAL MEDICINE; HUMAN; LOW DRUG DOSE; MAJOR DEPRESSION; MEMORY; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC SYSTEM; PATHOPHYSIOLOGY; REGULATORY MECHANISM; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC TRANSMISSION; SIGNAL TRANSDUCTION; SYMPTOM; TREATMENT DURATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY; DEPRESSIVE DISORDER, MAJOR; HUMANS; NEUROPROTECTIVE AGENTS; RECEPTORS, SIGMA; SIGNAL TRANSDUCTION;

EID: 67651033692     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.40     Document Type: Review

References (103)

1. Martin WR, Eades CG, Thompson JA et al. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197(3), 517-532 (1976).
2. Vaupel DB. Naltrexone fails to antagonize the σ effects of PCP and SKF10,047 in the dog. Eur. J. Pharmacol. 92(3-4), 269-274 (1983).
3. Quirion R, Chichportiche R, Contreras P et al. Classification and nomenclature of phencyclidine and σ receptor sites. Trends Neurol. Sci. 10, 444-446 (1987).
4. Bermack JE, Debonnel G. The role of σ receptors in depression. J. Pharmacol. Sci. 97 (3), 317-336 (2005). ••Attempts to compile the role of the σ-receptor in major depression.
5. Skuza G, Wedzony K. Behavioral pharmacology of σ-ligands. Pharmacopsychiatry 37(3), S183-S188 (2004).
6. Su TP, Hayashi T. Understanding the molecular mechanism of σ-1 receptors: towards a hypothesis that σ-1 receptors are intracellular amplifiers for signal transduction. Curr. Med. Chem. 10(20), 2073-2080 (2003) ••Explores the molecular mechanism of action of s-receptor ligands. (Pubitemid 37139064)
7. Debonnel G. Current hypotheses on σ receptors and their physiological role: possible implications in psychiatry. J. Psychiatry Neurosci. 18(4), 157-172 (1993). (Pubitemid 23255881)
8. 2+ signaling and cell survival. Cell 131(3), 596-610 (2007). •Demonstrates that σ-1 receptor protein is a ligand-operated receptor chaperone at mitochondrion-associated endoplasmic reticulum membrane.
9. Fontanilla D, Johannessen M, Hajipour AR et al. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous σ-1 receptor regulator. Science 323(5916), 934-937 (2009).
10. 2+: clinical and therapeutic relevance. Biol. Cell 97(12), 873-883 (2005).
11. Maurice T, Su TP, Privat A. Sigma1 (σ 1) receptor agonists and neurosteroids attenuate B25-35-amyloid peptide-induced amnesia in mice through a common mechanism. Neuroscience 83(2), 413-428 (1998). (Pubitemid 128680025)
12. Matsuno K. Anti-amnesic effects of σ (σ)-receptor agonists. Nippon Yakurigaku Zasshi 114(1), 25-33 (1999).
13. Kamei H, Noda Y, Nabeshima T et al. Effects of σ receptor ligands on psychiatric disorders. Nihon Shinkei Seishin Yakurigaku Zasshi 23(5), 187-196 (2003). (Pubitemid 37370307)
14. Dhir A, Kulkarni SK. Involvement of σ-1 receptor modulation in the antidepressant action of venlafaxine. Neurosci. Lett. 420(3), 244-248 (2007). (Pubitemid 46856010)
15. Noda Y, Kamei H, Nabeshima T. σ-receptor ligands and anti-stress actions. Nippon Yakurigaku Zasshi 114(1), 43-49 (1999).
16. Volz HP, Stoll KD. Clinical trials with σ ligands. Pharmacopsychiatry 37(3), S214-S220 (2004).
17. Langa F, Codony X, Tovar V et al. Generation and phenotypic analysis of σ receptor type I (σ 1) knockout mice. Eur. J. Neurosci. 18(8), 2188-2196 (2003). (Pubitemid 38117392)
18. Meunier J, Demeilliers B, Célérier A et al. Compensatory effect by σ1 (σ1) receptor stimulation during alcohol withdrawal in mice performing an object recognition task. Behav. Brain Res. 166(1), 166-176 (2006). (Pubitemid 41677372)
19. Sheps DS, Sheffield D. Depression, anxiety, and the cardiovascular system: the cardiologist's perspective. J. Clin. Psychiatry 62(8), 12-16 (2001). (Pubitemid 32429958)
20. Rumsfeld JS, Ho PM. Depression and cardiovascular disease: a call for recognition. Circulation 111(3), 250-253 (2005).
21. Licinio J, Wong ML. Depression, antidepressants and suicidality: a critical appraisal. Nat. Rev. Drug Discov. 4(2), 165-171 (2005). (Pubitemid 40277496)
22. Vijayakumar L. Suicide and mental disorders in Asia. Int. Rev. Psychiatry 17(2), 109-114 (2005).
23. Hanner M, Moebius FF, Flandorfer A et al. Purification, molecular cloning, and expression of the mammalian σ1-binding site. Proc. Natl. Acad. Sci. USA 93(15), 8072-8077 (1996). (Pubitemid 26277167)
24. Kekuda R, Prasad PD, Fei YJ et al. Cloning and functional expression of the human type 1 σ receptor (hσR1). Biochem. Biophys. Res. Commun. 229(2), 553-558 (1996). ••Depicts the cloning of σ-1 receptors. (Pubitemid 27029069)
25. Seth P, Leibach FH, Ganapathy V. Cloning and structural analysis of the cDNA and the gene encoding the murine type 1 σ receptor. Biochem. Biophys. Res. Commun. 241(2), 535-540 (1997). (Pubitemid 28020136)
26. Seth P, Fei YJ, Li HW et al. Cloning and functional characterization of a σ receptor from rat brain. J. Neurochem. 70(3), 922-931 (1998). (Pubitemid 28113624)
27. Leitner ML, Hohmann AG, Patrick SL et al. Regional variation in the ratio of σ 1 to σ 2 binding in rat brain. Eur. J. Pharmacol. 259(1), 65-69 (1994).
28. 3H]-1-[1-(2-thienyl)cyclohexyl] piperidine. J. Pharmacol. Exp. Ther. 238, 739-748 (1986).
29. Gundlach AL, Largent BL, Snyder SH. Autoradiographic localization of σ receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. J. Neurosci. 6(6), 1757-1770 (1986). •Explores the location of σ-1 receptors in the brains of rats and guinea pigs.
30. Kitaichi K, Chabot JG, Moebius FF et al. Expression of the purported σ(1) receptor in the mammalian brain and its possible relevance in deficits induced by antagonism of the NMDA receptor complex as revealed using an antisense strategy. J. Chem. Neuroanat. 20(3-4), 375-387 (2000). (Pubitemid 32162893)
31. Phan VL, Urani A, Sandillon F et al. Preserved σ1 (σ1) receptor expression and behavioral efficacy in the aged C57BL/6 mouse. Neurobiol. Aging 24(6), 865-881 (2003). (Pubitemid 37288860)
32. 2+ concentration. J. Pharmacol. Exp. Ther. 293(3), 788-798 (2000). •Attempts to study the mechanism of action of various σ-receptor ligands.
33. Hayashi T, Su TP. Regulating ankyrin dynamics: roles of σ-1 receptors. Proc. Natl Acad. Sci. USA 98(2), 491-496 (2001). (Pubitemid 32105069)
34. Hong W, Nuwayhid SJ, Werling LL. Modulation of bradykinin-induced calcium changes in SH-SY5Y cells by neurosteroids and σ receptor ligands via a shared mechanism. Synapse 54, 102-110 (2004). (Pubitemid 39315095)
35. Urani A, Romieu P, Portales-Casamar E et al. The antidepressant-like effect induced by the σ(1) (σ(1)) receptor agonist igmesine involves modulation of intracellular calcium mobilization. Psychopharmacology (Berl.) 163(1), 26-35 (2002). ••Attempts to explain the mechanism of antidepressant action of igmesine, one of the σ-1 receptor modulators. (Pubitemid 34985309)
36. Aydar E, Palmer CP, Klyachko VA et al. The σ receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 34(3), 399-410 (2002). (Pubitemid 34465498)
37. Monnet FP, Debonnel G, Junien JL et al. N-methyl-D-aspartate- induced neuronal activation is selectively modulated by σ receptors. Eur. J. Pharmacol. 179(3), 441-445 (1990).
38. Martina M, Turcotte ME, Halman S et al. The σ-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus. J. Physiol. 578(1), 143-157 (2007). (Pubitemid 44971116)
39. 1 receptor ligand. Expert Opin. Ther. Targets 12(1), 45-58 (2008).
40. Bergeron R, de Montigny C, Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via σ receptors. J. Neurosci. 16(3), 1193-11120 (1996). (Pubitemid 26140876)
41. Nuwayhid SJ, Werling LL. Steroids modulate N-methyl-D-aspartate- stimulated [3H] dopamine release from rat striatum via σ receptors. J. Pharmacol. Exp. Ther. 306(3), 934-940 (2003).
42. Collier TL, Waterhouse RN, Kassiou M. Imaging σ receptors: applications in drug development. Curr. Pharm. Des. 13(1), 51-72 (2007). (Pubitemid 46085297)
43. Hashimoto K, Ishiwata K. σ receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr. Pharm. Des. 12(30), 3857-3876 (2006) (Pubitemid 44560699)
44. Hayashi T, Su TP. σ-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 18(5), 269-284 (2004). •Extensive review summarizing various σ-1 receptor ligands. (Pubitemid 38526712)
45. Debonnel G, de Montigny C. Modulation of NMDA and dopaminergic neurotransmissions by σ ligands: possible implications for the treatment of psychiatric disorders. Life Sci. 58(9), 721-734 (1996). (Pubitemid 126334914)
46. Nabeshima T, Okuyama S. Physiological function of σ receptors: central pharmacological effects of σ ligand. Nihon Shinkei Seishin Yakurigaku Zasshi. 14(2), 51-76 (1994). (Pubitemid 24185926)
47. Levi MS, Brimble MA. A review of neuroprotective agents. Curr. Med. Chem. 11(18), 2383-2397 (2004).
48. Nakazawa M, Matsuno K, Mita S. Activation of σ1 receptor subtype leads to neuroprotection in the rat primary neuronal cultures. Neurochem. Int. 32(4), 337-343 (1998). (Pubitemid 28174985)
49. Bhardwaj A, Sawada M, London ED et al. Potent σ1-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine modulates basal and N-methyl-D- aspartate-evoked nitric oxide production in vivo. Stroke 29(11), 2404-2410 (1998)
50. Brammer MK, Gilmore DL, Matsumoto RR. Interactions between 3,4-methylenedioxymethamphetamine and σ1 receptors. Eur. J. Pharmacol. 553(1-3), 141-145 (2006).
51. Lysko PG, Gagnon RC, Yue TL et al. Neuroprotective effects of SKF 10,047 in cultured rat cerebellar neurons and in gerbil global brain ischemia. Stroke 23(9), 414-419 (1992).
52. Beltran D, Cavas M, Navarro JF. Effects of (+)SKF 10047, a σ-1 selective agonist, on isolation-induced aggression in male mice. Methods Find. Exp. Clin. Pharmacol. 28(9), 601 (2006) (Pubitemid 46133008)
53. Narita M, Yoshizawa K, Aoki K et al. A putative σ1 receptor antagonist NE-100 attenuates the discriminative stimulus effects of ketamine in rats. Addict. Biol. 6(4), 373-376 (2001). (Pubitemid 32946752)
54. Takebayashi M, Hayashi T, Su TP. Nerve growth factor-induced neurite sprouting in PC12 cells involves σ-1 receptors: implications for antidepressants. J. Pharmacol. Exp. Ther. 303(3),1227-1237 (2002). (Pubitemid 35424409)
55. Narita N, Hashimoto K, Tomitaka S et al. Interactions of selective serotonin reuptake inhibitors with subtypes of σ receptors in rat brain. Eur. J. Pharmacol. 307(1), 117-119 (1996). (Pubitemid 26226293)
56. Ishikawa M, Ishiwata K, Ishii K et al. High occupancy of σ-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol. Psychiatry 62(8), 829-946 (2007) (Pubitemid 47488223)
57. Maurice T, Hiramatsu M, Itoh J et al. Behavioral evidence for a modulating role of σ ligands in memory processes. I. Attenuation of dizocilpine (MK-801)-induced amnesia. Brain Res. 647(1), 44-56 (1994). (Pubitemid 24154500)
58. Bergeron R, de Montigny C, Debonnel G. Biphasic effects of σ ligands on the neuronal response to N-methyl-D-aspartate. Naunyn Schmiedeberg's Arch. Pharmacol. 351(3), 252-260 (1995).
59. 3H]-noradrenaline release in rat hippocampal slices. Br. J. Pharmacol. 119(1), 65-72 (1996).
60. Dhir A, Kulkarni SK. Involvement of σ (σ1) receptors in modulating the anti-depressant effect of neurosteroids (dehydroepiandrosterone or pregnenolone) in mouse tail-suspension test. J. Psychopharmacol. 22(6), 691-696 (2008).
61. Amano M, Yamada K, Matsuno K et al. Neuropharmacological effects of σ receptor ligands: anxiolytic, anti-amnesic and neuroprotective effects. Nihon Shinkei Seishin Yakurigaku Zasshi 16(3), 73-84 (1996). (Pubitemid 26286865)
62. 2+ influx in rat cortical neurons. J. Pharmacol. Exp. Ther. 327(2), 491-502 (2008).
63. 1 receptors in amelioration of conditioned fear stress in rats: association with mesolimbic dopaminergic systems. Eur. J. Pharmacol. 319 (2-3), 165-172 (1997).
64. Sabino V, Cottone P, Parylak SL et al. σ-1 receptor knockout mice display a depressive-like phenotype. Behav. Brain Res. 198(2), 472-476 (2009).
65. Skuza G. Potential antidepressant activity of σ ligands. Pol. J. Pharmacol. 55(6), 923-934 (2003). •Depicts the antidepressant activity of various σ receptor ligands.
66. Matsuno K, Kobayashi T, Tanaka M.K et al. σ 1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur. J. Pharmacol. 312(3), 267-271 (1996). (Pubitemid 26323508)
67. Urani A, Romieu P, Roman FJ et al. Enhanced antidepressant efficacy of σ1 receptor agonists in rats after chronic intracerebroventricular infusion of β-amyloid-(1-40) protein. Eur. J. Pharmacol. 486(2), 151-161 (2004). (Pubitemid 38224526)
68. Ukai M, Maeda H, Nanya Y et al. Beneficial effects of acute and repeated administrations of σ receptor agonists on behavioral despair in mice exposed to tail suspension. Pharmacol. Biochem. Behav. 61(3), 247-252 (1998). (Pubitemid 28498207)
69. Oshiro Y, Sakurai Y, Sato S et al. 3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3- chlorophenyl)-1-piperazinyl]propyl]-3,4-dihydro-5-methoxy-2(1H)-quinolinone and its derivatives. J. Med. Chem. 43, 177-189 (2000). (Pubitemid 30078149)
70. Reddy DS, Kaur G, Kulkarni SK. σ (σ1) receptor mediated anti-depressant-like effects of neurosteroids in the Porsolt forced swim test. Neuroreport 9(13), 3069-3073 (1998). •Depicts the involvement of σ-1 receptors in the antidepressant-like activity of neurosteroids in the forced swim test, an animal model of behavioral despair. (Pubitemid 28555648)
71. Chaki S, Nakazato A, Kennis L et al. Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450. Eur. J. Pharmacol. 485(1-3), 145-158 (2004). (Pubitemid 38134409)
72. Wang J, Mack AL, Coop A et al. Novel σ (σ) receptor agonists produce antidepressant-like effects in mice. Eur. Neuropsychopharmacol. 17(11), 708-716 (2007). (Pubitemid 47419291)
73. Phan VL, Miyamoto Y, Nabeshima T et al. Age-related expression of σ1 receptors and antidepressant efficacy of a selective agonist in the senescence-accelerated (SAM) mouse. J. Neurosci. Res. 79(4), 561-572 (2005). (Pubitemid 40283356)
74. Takebayashi M, Hayashi T, Su TP. A perspective on the new mechanism of antidepressants: neuritogenesis through σ-1 receptors. Pharmacopsychiatry 37(3), S208-S213 (2004). (Pubitemid 39578130)
75. Kikuchi-Utsumi K, Nakaki T. Chronic treatment with a selective ligand for the σ-1 receptor chaperone, SA4503, up-regulates BDNF protein levels in the rat hippocampus. Neurosci. Lett. 440(1), 19-22 (2008).
76. Waterhouse RN, Chang RC, Atuehene N et al. In vitro and in vivo binding of neuroactive steroids to the σ-1 receptor as measured with the positron emission tomography radioligand [18F]FPS. Synapse 61(7), 540-546 (2007) (Pubitemid 46759492)
77. Horan B, Gifford AN, Matsuno K et al. Effect of SA4503 on the electrically evoked release of (3)H-acetylcholine from striatal and hippocampal rat brain slices. Synapse 46(1), 1-3 (2002). (Pubitemid 34969199)
78. Maurice T, Phan VL, Privat A. The anti-amnesic effects of σ1 (σ1) receptor agonists confirmed by in vivo antisense strategy in the mouse. Brain Res. 898(1), 113-121 (2001). (Pubitemid 32274198)
79. Maurice T, Junien JL, Privat A. Dehydroepiandrosterone sulfate attenuates dizocilpine-induced learning impairment in mice via σ 1-receptors. Behav. Brain Res. 83(1-2), 159-164 (1997). (Pubitemid 27086630)
80. Gronier B, Debonnel G. Involvement of σ receptors in the modulation of the glutamatergic/NMDA neurotransmission in the dopaminergic systems. Eur. J. Pharmacol. 368(2-3), 183-196 (1999). (Pubitemid 29117139)
81. Meurs A, Clinckers R, Ebinger G et al. σ 1 receptor-mediated increase in hippocampal extracellular dopamine contributes to the mechanism of the anticonvulsant action of neuropeptide Y. Eur. J. Neurosci. 26(11), 3079-3092 (2007). (Pubitemid 350135171)
82. Peeters M, Romieu P, Maurice T et al. Involvement of the σ 1 receptor in the modulation of dopaminergic transmission by amantadine. Eur. J. Neurosci. 19(8), 2212-2220 (2004). (Pubitemid 38582209)
83. Paquette MA, Brudney EG, Putterman DB et al. σ ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias. Neuroreport 19(1), 111-115 (2008).
84. Dong LY, Cheng ZX, Fu YM et al. Neurosteroid dehydroepiandrosterone sulfate enhances spontaneous glutamate release in rat prelimbic cortex through activation of dopamine D1 and σ-1 receptor. Neuropharmacology 52(3), 966-974 (2007).
85. Cobos EJ, del Pozo E, Baeyens JM. Irreversible blockade of σ-1 receptors by haloperidol and its metabolites in guinea pig brain and SH-SY5Y human neuroblastoma cells. J. Neurochem. 102(3), 812-825 (2007).
86. Inoue A, Sugita S, Shoji H et al. Repeated haloperidol treatment decreases σ(1) receptor binding but does not affect its mRNA levels in the guinea pig or rat brain. Eur. J. Pharmacol. 401(3), 307-316 (2000). (Pubitemid 30608714)
87. Kobayashi T, Matsuno K, Murai M et al. σ 1 receptor subtype is involved in the facilitation of cortical dopaminergic transmission in the rat brain. Neurochem. Res. 22(9), 105-109 (1997). (Pubitemid 27327936)
88. 1A receptor agonist in the forced swimming test in rats. Pharmacol. Rep. 59(6), 773-777 (2007).
89. Reddy DS, Kulkarni SK. Role of GABA-A and mitochondrial diazepam binding inhibitor receptors in the anti-stress activity of neurosteroids in mice. Psychopharmacology (Berl.) 128(3), 280-292 (1996).
90. Peyron C, Petit JM, Rampon C et al. Forebrain afferents to the rat dorsal Raphe nucleus demonstrated by retrograde and anterograde tracing methods. Neuroscience 82(2), 443-468 (1998). (Pubitemid 27461632)
91. Dhir A, Kulkarni SK. Possible involvement of σ-1 receptors in the anti-immobility action of bupropion, a dopamine reuptake inhibitor. Fundam. Clin. Pharmacol. 22(4), 387-394 (2008).
92. 3H]norepinephrine release evoked by N-methyl-D-aspartate in the rat hippocampus. Proc. Natl Acad. Sci. USA 92(9), 3774-3778 (1995).
93. Skuza G, Rogoz Z. Effect of combined treatment with selective σ ligands and amantadine in the forced swimming test in rats. Pol. J. Pharmacol. 54(6), 699-702 (2002). (Pubitemid 36124522)
94. Skuza G, Rogoz Z. The synergistic effect of selective σ receptor agonists and uncompetitive NMDA receptor antagonists in the forced swim test in rats. J. Physiol. Pharmacol. 57(2), 217-229 (2006). (Pubitemid 44077747)
95. Nuwayhid SJ, Werling LL. σ1 receptor agonist-mediated regulation of N-methyl-D-aspartate-stimulated [3H]dopamine release is dependent upon protein kinase C. J. Pharmacol. Exp. Ther. 304, 364-369 (2003).
96. Kulkarni SK, Dhir A. On the mechanism of antidepressant-like action of berberine chloride. Eur. J. Pharmacol. 589(1-3), 163-172 (2008).
97. Dhir A, Kulkarni SK. Antidepressant-like effect of 17β-estradiol: involvement of dopaminergic, serotonergic, and (or) σ-1 receptor systems. Can. J. Physiol. Pharmacol. 86, 726-735 (2008).
98. Frieboes RM, Murck H, Wiedemann K et al. Open clinical trial on the σ ligand panamesine in patients with schizophrenia. Psychopharmacology (Berl.) 132(1), 82-88 (1997). (Pubitemid 27303743)
99. Pande AC, Geneve J, Scherrer B. Igmesine, a novel σ ligand, has antidepressant properties. Presented at: Congress of Collegium Internationale Neuro-Psychopharmacologicum. 5-10 July, Glasgow, UK 1998. ••Clinical study demonstrating the effect of the σ-1 receptor agonist, igmesine, in major depression.
100. Hans-Jurgen M, Hans-Peter V, Ingrid RW et al. Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J. Clin. Psychopharmacol. 21(1), 59-65 (2001).
101. Hirata H, Sonoda S, Agui S et al. Rubiscolin-6, a δ opioid peptide derived from spinach Rubisco, has anxiolytic effect via activating σ1 and dopamine D1 receptors. Peptides 28(10), 1998-2003 (2007).
102. Mamiya T, Noda Y, Noda A et al. Effects of σ receptor agonists on the impairment of spontaneous alternation behavior and decrease of cyclic GMP level induced by nitric oxide synthase inhibitors in mice. Neuropharmacology 39(12), 2391-2398 (2000). (Pubitemid 30642782)
103. Maayan R, Touati-Werner D, Ram E et al. The protective effect of frontal cortex dehydroepiandrosterone in anxiety and depressive models in mice. Pharmacol. Biochem. Behav. 85(2), 415-421 (2006). (Pubitemid 44881083)